Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
ConditionEngraftment Syndrome
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorHenry Ford Health System
About this trial
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
Eligibility criteria
Qualifiers
• Patients 18-80 years of age with a diagnosis of a hematological malignancy
Meet the BMT program criteria to undergo hematopoietic stem cell transplantation for hematologi malignancies
Disqualifiers
• Patients enrolled in investigational clinical trials
Sct for non hematologic malignancies
Trial design
Treatments tested in this trial
- Budesonide
Treatment groups
110 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov